Your browser doesn't support javascript.
loading
The Assessment of Major Histocompatibility Complex (MHC) Class-I Expression in Different Neuromuscular Diseases.
Kurdi, Maher; Alshareef, Aysha; Bamaga, Ahmed K; Fadel, Zahir T; Alrawaili, Moafaq S; Hakamy, Sahar; Mohamed, Fawaz; Abuzinadah, Ahmad R; Addas, Bassam M J; Butt, Nadeem Shafique.
Afiliação
  • Kurdi M; Department of Pathology, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia.
  • Alshareef A; Neuromuscular Unit, Roya Medical Specialized Laboratories, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Bamaga AK; Department of Internal Medicine, King Abdulaziz University Hospital and Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Fadel ZT; Neurology Division, Department of Pediatrics, Faculty of Medicine, King Abdulaziz University and Hospital, Jeddah, Saudi Arabia.
  • Alrawaili MS; Department of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Hakamy S; Department of Internal Medicine, King Abdulaziz University Hospital and Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Mohamed F; Neuromuscular Unit, Roya Medical Specialized Laboratories, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Abuzinadah AR; Department of Pathology, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia.
  • Addas BMJ; Neuromuscular Unit, Roya Medical Specialized Laboratories, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Butt NS; Department of Internal Medicine, King Abdulaziz University Hospital and Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Article em En | MEDLINE | ID: mdl-35002356
ABSTRACT

BACKGROUND:

Major histocompatibility complex (MHC) class-1 antigen is a glycoprotein expressed in all nucleated cells. The aim of this study was to assess MHC class-I expression in different neuromuscular diseases.

METHODS:

The authors reviewed the data of 54 patients with neuromuscular diseases. Anti MHC class-I antibody was performed on the frozen muscle tissues using immunohistochemistry. MHC class-I was scored based on its expression on muscle fibers (0 normal, 1 expression <5 fibers, 2 expression in 5-10 fibers, 3 expression in >10 fibers). The pattern was only assessed in cases with MHC class-I scored 3 as (1 Sarcocapillary, 2 Sarcocapillary and necrotic fibers, 3 Perifascicular). The relationship between MHC class-I expression and neuromuscular diseases was statistically analyzed.

RESULTS:

The mean age of the patients was 39.1 ± 18.5 years. Around 50% of patients showed normal CK levels and 5% of the cases showed elevated CK levels. There was a significance difference in MHC class-I expression between cases with normal and elevated CK levels when MHC class-I score was 3 (p= 0.020). There was a significant difference in MHC class-I expression among different neuromuscular diseases (p<0.001). All cases with idiopathic inflammatory myopathies (IIMs) have expressed MHC class-I in more than 10 fibers. MHC class-I was expressed in 15 cases of non-IIMs.

CONCLUSION:

MHC class-I cannot be solely used as a biomarker to distinguish IIMs from non-IIMs. The presence of MHC class-I molecules in non-IIMs might be related to immunoproteasomes mechanism. Further studies, with different muscle proteins expression and genomic sequencing, must be conducted to understand the role of MHC Class-I in neuromuscular diseases.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Degener Neurol Neuromuscul Dis Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Degener Neurol Neuromuscul Dis Ano de publicação: 2021 Tipo de documento: Article